Treatment variation in prostate cancer is common, and it is driven by clinical and clinician factors, patient preferences, availability of resources, and access to physicians and treating facilities. Most research on treatment disparities in men with prostate cancer has focused on race and socioeconomic factors. However, the geography of disparities — capturing racial and socioeconomic differences based on where patients live — can provide insight into barriers to care and help identify outlier areas in which access to care, health resources, or both are more pronounced.
Methods
Research regarding treatment patterns and disparities in prostate cancer using the Geographical Information System (GIS) was searched. Studies were limited to English-language articles and research focused on US populations. A total of 43 articles were found; of those, 30 provided information about or used spatial or geographical analyses to assess and describe differences or disparities in prostate cancer and its treatment. Two additional GIS resources were included.
Results
The research on geographical and spatial determinants of prostate cancer disparities was reviewed. We also examined geographical analyses at the state level, focusing on Florida. Overall, we described a geographical framework to disparities that affect men with prostate cancer and reviewed existing published evidence supporting the interplay of geographical factors and disparities in prostate cancer.
Conclusions
Disparities in prostate cancer are common and persistent, and notable differences in treatment are observable across racial and socioeconomic strata. Geographical analysis provides additional information about where disparate groups live and also helps to map access to care. This information can be used by public health officials, health-systems administrators, clinicians, and policymakers to better understand and respond to geographical barriers that contribute to disparities in care.
References
1.
SiegelR.L., MillerK.D., JemalA.Cancer statistics, 2016.CA Cancer J Clin.2016; 66(1): 7–30.
AlbertsenP.C., HanleyJ.A., FineJ.20-year outcomes following conservative management of clinically localized prostate cancer.JAMA.2005; 293(17): 2095–2101.
5.
D'AmicoA.V., WhittingtonR., MalkowiczB.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.JAMA.1998; 280(11): 969–974.
6.
FreedlandS.J., HumphreysE.B., MangoldL.A.Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.JAMA.2005; 294(4): 433–439.
7.
RoehrbornC.G., BlackL.K.The economic burden of prostate cancer.BJU Int.2011; 108(6): 806–813.
8.
PettawayC.A.Racial differences in the androgen/androgen receptor pathway in prostate cancer.J Natl Med Assoc.1999; 91(12): 653–660.
9.
WardE., JemalA., CokkinidesV.Cancer disparities by race/ethnicity and socioeconomic status.CA Cancer J Clin.2004; 54(2): 78–93.
10.
WoodsL.M., RachetB., ColemanM.P.Origins of socio-economic inequalities in cancer survival: a review.Ann Oncol.2006; 17(1): 5–19.
11.
BennettC.L., FerreiraM.R., DavisT.C.Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer.J Clin Oncol.1998; 16(9): 3101–3104.
12.
AnejaS., YuJ.B.The impact of county-level radiation oncologist density on prostate cancer mortality in the United States.Prostate Cancer Prostatic Dis.2012; 15(4): 391–396.
13.
AntwiS., TuckerT.C., CokerA.L.Racial disparities in survival after diagnosis of prostate cancer in Kentucky, 2001-2010.Am J Mens Health.2013; 7(4): 306–316.
14.
CetnarJ.P., HamptonJ.M., WilliamsonA.A.Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in Wisconsin.Urology.2013; 81(3): 540–546.
15.
CobranE.K., ChenR.C., OvermanR.Racial differences in diffusion of intensity-modulated radiation therapy for localized prostate cancer.Am J Mens Health.2015; 10(5): 399–407.
16.
CookM.B., RosenbergP.S., McCartyF.A.Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008.Prostate.2015; 75(7): 758–763.
17.
DeChelloL.M., GregorioD.I., SamociukH.Race-specific geography of prostate cancer incidence.Int J Health Geogr.2006; 5: 59.
18.
GargV., RaischD.W., SeligJ.P.Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis.Prostate Cancer Prostatic Dis.2013; 16(2): 193–203.
19.
GoovaertsP., XiaoH.Geographical, temporal and racial disparities in late-stage prostate cancer incidence across Florida: a multiscale join-point regression analysis.Int J Health Geogr.2011; 10: 63.
20.
GregorioD.I., HuangL., DeChelloL.M.Place of residence effect on likelihood of surviving prostate cancer.Ann Epidemiol.2007; 17(7): 520–524.
21.
MelikerJ.R., GoovaertsP., JacquezG.M.Breast and prostate cancer survival in Michigan: can geographic analyses assist in understanding racial disparities?Cancer.2009; 115(10): 2212–2221.
22.
OnukwughaE., OsteenP., JayasekeraJ.Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors.Cancer.2014; 120(21): 3385–3392.
23.
WagnerS.E., BauerS.E., BayaklyA.R., VenaJ.E.Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends.Cancer Cause Control.2013; 24(1): 153–166.
24.
XiaoH., GwedeC.K., KirosG.Analysis of prostate cancer incidence using geographic information system and multilevel modeling.J Natl Med Assoc.2007; 99(3): 218–225.
25.
XiaoH., TanF., GoovaertsP.Racial and geographic disparities in late-stage prostate cancer diagnosis in Florida.J Health Care Poor Underserv.2011; 22(4 suppl): 187–199.
26.
SiegelR.L., MillerK.D., JemalA.Cancer statistics, 2015.CA Cancer J Clin.2015; 65(1): 5–29.
27.
MahalB.A., AizerA.A., ZiehrD.R.Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups.Urology.2014; 84(2): 386–392.
28.
BarocasD.A., GrubbRIII, BlackA.Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian screening trial.Cancer.2013; 119(12): 2223–2239.
29.
ZeliadtS.B., PotoskyA.L., EtzioniR.Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.Urology.2004; 64(6): 1171–1176.
30.
KleinJ., von den KnesebeckO.Socioeconomic inequalities in prostate cancer survival: a review of the evidence and explanatory factors.Soc Sci Med.2015; 142: 9–18.
31.
ChornokurG., DaltonK., BorysovaM.E.Disparities at presentation, diagnosis, treatment, and survival in African American men affected by prostate cancer.Prostate.2011; 71: 985–997.
32.
AuvivenA., KarjalainenS.Possible explanations for social class differences in cancer patient survival.IARC Sci Publ.1997; 138: 377–397.
33.
WoodsV.D., MontgomeryS.B., HerringR.P.Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.J Natl Med Assoc.2006; 98(4): 492–504.
34.
FairleyL., BakerM., WhitewayJ.Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006.Br J Cancer.2009; 101(11): 1839–1845.
35.
HayenA., SmithD.P., PatelM.I.Patterns of surgical care for prostate cancer in NSW, 1993-2002: rural/urban and socioeconomic variation.Aust N Z J Public Health.2008; 32(5): 417–420.
36.
KrupskiT.L., KwanL., AfifiA.A.Geographic and socioeconomic variation in the treatment of prostate cancer.J Clin Oncol.2005; 23(31): 7881–7888.
37.
LyratzopoulosG., BarbiereJ.M., GreenbergD.C.Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in the UK region: continuous survey.BMJ.2010; 240: c1928.
38.
RossL.E., TaylorY.J., HowardD.L.Trends in prostate-specific antigen test use, 2000-2005.Public Health Rep.2011; 126(2): 228–239.
39.
WilliamsN., HughesL.J., TurnerE.L.Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.BJU Int.2011; 108(9): 1402–1408.
40.
YinH.S., DreyerB.P., VivarK.L.Perceived barriers to care and attitudes towards shared decision-making among low socioeconomic status parents: role of health literacy.Acad Pediatr.2012; 12(2): 117–124.
41.
ZiehrD.R., MahalB.A., AizerA.A.Income inequality and treatment of African American men with high-risk prostate cancer.Urol Oncol.2015; 33: 18e7–e13.
42.
HarlanL., BrawleyO., PommerenkeF.Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate.J Clin Oncol.1995; 13(1): 93–100.
43.
JemalA., WardE., WuX.Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.Cancer Epidemiol Biomark Prevent.2005; 14(3): 590–595.
44.
JonesA.P., HaynesR., SauerzapfV.Travel times to health care and survival from cancers in Northern England.Eur J Cancer.2008; 44(2): 269–274.
45.
ObertovaZ., BrownC., HolmesM.Prostate cancer and mortality in rural men – a systematic review of the literature.Rural Remote Health.2012; 12(2): 2039.
46.
PruthiR.S., TornehlC., GastonK.Impact of race, age, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in siblings of patients with prostate cancer.Eur Urol.2006; 50(1): 64–69.
47.
KohH.K., JudgeC.M., FerrerB.Using public health data systems to understand and eliminate cancer disparities.Cancer Cause Control.2005; 16(1): 15–26.
48.
XiaoH., TanF., GoovaertsP.Multilevel factors associated with overall mortality for men diagnosed with prostate cancer in Florida.Am J Mens Health.2014; 8(4): 316–326.
49.
XiaoH., TanF., AdunlinG.Factors associated with overall survival prostate cancer in Florida: a multilevel analysis.J Health Care Poor Underserved.2015; 26(1): 266–277.
50.
CoppockJ.T., RhindD.W.The history of GIS. In: LongleyP.A., Good-childM.F., MaguireD.J., eds. Geographical Information Systems.Hoboken, NJ: John Wiley & Sons; 1991: 21–43. http://www.wiley.com/legacy/wileychi/gis/Volume1/BB1v1_ch2.pdf. Accessed September 21, 2016.
51.
KriegerN., ChenJ.T., WatermanP.D.Choosing area based socioeconomic measures to monitor social inequities in low birth weight and childhood lead poisoning: The Public Health Disparities Geocoding Project (US).J Epidemiol Commun Health.2003; 57(3): 186–199.
52.
National Cancer Institute.Geographic information systems and science for cancer control.https://gis.cancer.gov. Accessed September 21, 2016.
53.
CockburnM., MillsP., ZhangX.Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California.Am J Epidemiol.2011; 173(11): 1280–1288.
54.
MarusekJ.C., CockburnM.G., MillsP.K.Control selection and pesticide exposure assessment via GIS in prostate cancer studies.Am J Prev Med.2006; 30(2 suppl): S109–S116.
55.
CaryC., OdishoA.Y., CooperbergM.R.Variation in prostate cancer treatment associated with population density of the county of residence.Prostate Cancer Prostatic Dis.2016; 19(2): 174–179.
56.
HsuC.E., MasF.S., MillerJ.A.A spatial-temporal approach to surveillance of prostate cancer disparities in population subgroups.J Natl Med Assoc.2007; 99(1): 72–80, 85-77.
57.
DeanL.T., SubramanianS.V., WilliamsD.R.Getting black men to undergo prostate cancer screening: the role of social capital.Am J Mens Health.2015; 9(5): 385–396.
58.
WagnerS.E., BurchJ.B., HusseyJ.Soil zinc content, groundwater usage, and prostate cancer incidence in South Carolina.Cancer Cause Control.2009; 20(3): 345–353.
59.
FoglemanA.J., MuellerG.S., JenkinsW.D.Does where you live play an important role in cancer incidence in the U.S.?Am J Cancer Res.2015; 5(7): 2314–2319.
60.
Lu-YaoG., AlbertsenP.C., StanfordJ.L.Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.J Gen Intern Med.2008; 23(11): 1809–1814.
61.
MossanenM., IzardJ., WrightJ.L.Identification of underserved areas for urologic cancer care.Cancer.2014; 120(10): 1565–1571.
62.
WagnerS.E., HurleyD.M., HebertJ.R.Cancer mortality-to-incidence ratios in Georgia: describing racial cancer disparities and potential geographic determinants.Cancer.2012; 118(16): 4032–4045.
63.
WanN., ZhanF.B., CaiZ.Socioeconomic disparities in prostate cancer mortality and the impact of geographic scale.South Med J.2011; 104(8): 553–559.
64.
GoovaertsP., XiaoH.The impact of place and time on the proportion of late-stage diagnosis: the case of prostate cancer in Florida, 1981-2007.Spat Spatiotemporal Epidemiol.2012; 3(3): 243–253.
65.
GoovaertsP., XiaoH., AdunlinG.Geographically-weighted regression analysis of percentage of late-stage prostate cancer diagnosed in Florida.Appl Geogr.2015; 62: 191–200.
66.
XiaoH., WarrickC., HuangY.Prostate cancer treatment patterns among racial/ethnic groups in Florida.J Natl Med Assoc.2009; 101(9): 936–943.
67.
XiaoH., TanF., GoovaertsP.Factors associated with time-to-treatment of prostate cancer in Florida.J Health Care Poor Underserv.2013; 24(4 suppl): 132–146.
68.
OliverM.N., SmithE., SiadatyM.Spatial analysis of prostate cancer incidence and race in Virginia, 1990-1999.Am J Prev Med.2006; 30(suppl): S67–S76.
69.
KriegerN., WatermanP., ChenJ.T.Zip code caveat: bias due to spatiotemporal mismatches between zip codes and US census-defined geographic areas – the Public Health Disparities Project.Am J Pub Health.2002; 92(7): 1100–1102.
70.
GregorioD.I., DechelloL.M., SamociukH.Lumping or splitting: seeking the preferred areal unit for health geography studies.Int J Health Geogr.2005; 4(1): 6.
